The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer

Jin Xia^{1

2}, Wen-Zhao Zhong^{1

2}, Yi-Long Wu^{1

2}

Affiliations

¹ Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou 510080, China.
² Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangzhou 510080, China.

Comment

Jin Xia et al. J Thorac Dis. 2019 Jan.

. 2019 Jan;11(1):E11-E13.

doi: 10.21037/jtd.2018.12.72.

Jin Xia^{1

2}, Wen-Zhao Zhong^{1

2}, Yi-Long Wu^{1

2}

¹ Guangdong General Hospital, School of Medicine, South China University of Technology, Guangzhou 510080, China.
² Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangzhou 510080, China.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer-the more specific, the better?
Smolle E, Pichler M. Smolle E, et al. J Thorac Dis. 2018 Nov;10(Suppl 33):S3961-S3964. doi: 10.21037/jtd.2018.09.81. J Thorac Dis. 2018. PMID: 30631527 Free PMC article. No abstract available.

1. Smolle E, Pichler M. Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer—the more specific, the better? J Thorac Dis 2018;10:S3961-4. 10.21037/jtd.2018.09.81 - DOI - PMC - PubMed
1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed
1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed
1. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8. 10.1016/S1470-2045(09)70364-X - DOI - PubMed
1. Taylor MD, Nagji AS, Bhamidipati CM, et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg 2012;93:1813-20; discussion 1820-1. - PubMed